LTGO (Latigo Biotherapeutics) 3-1 Month Momentum %: N/A% (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.14
View Full Analysis

What is Latigo Biotherapeutics 3-1 Month Momentum %?

Latigo Biotherapeutics LTGO -0.60% 8 3-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus rates LTGO with a GF Score™ of 8/100. Among 1,382 Biotechnology companies, Latigo Biotherapeutics ranks worse than 72358.83% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-10), Latigo Biotherapeutics's 3-1 Month Momentum % is N/A%.

The industry rank for Latigo Biotherapeutics's 3-1 Month Momentum % or its related term are showing as below:

LTGO's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.2
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Latigo Biotherapeutics  (NAS:LTGO) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Latigo Biotherapeutics 3-1 Month Momentum % Related Terms

LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics  (NAS:LTGO) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Latigo Biotherapeutics (LTGO) has a 3-1 Month Momentum % of N/A% as of Aug. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Latigo Biotherapeutics and its competitors. According to the industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 1382 companies in the Biotechnology industry.
Is Latigo Biotherapeutics' 3-1 Month Momentum % too high?
Latigo Biotherapeutics' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Latigo Biotherapeutics ranks #999999 out of 1382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' 3-1 Month Momentum % compare to ?
According to the Biotechnology industry distribution chart, Latigo Biotherapeutics ranks #999999 out of 1382 companies for 3-1 Month Momentum %. This places Latigo Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current 3-1 Month Momentum % is N/A% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.14
Price